Deferred Tax Assets, Valuation Allowance of Immunome Inc. from 31 Dec 2019 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Immunome Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2019 to 31 Dec 2025.
  • Immunome Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $152,318,000, a 43% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Immunome Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $152,318,000 +$45,598,000 +43% 31 Dec 2025 10-K 03 Mar 2026 2025 FY
Q4 2024 $106,720,000 +$66,893,000 +168% 31 Dec 2024 10-K 03 Mar 2026 2025 FY
Q4 2023 $39,827,000 +$9,218,000 +30% 31 Dec 2023 10-K 03 Mar 2026 2025 FY
Q4 2022 $30,609,000 +$7,354,000 +32% 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q4 2021 $23,255,000 +$7,820,000 +51% 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q4 2020 $15,435,000 +$3,724,000 +32% 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q4 2019 $11,711,000 31 Dec 2019 10-K 25 Mar 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.